Interpretation of the prostate-specific antigen history in assessing life-threatening prostate cancer

BJU International

Volumn 106, Issue 9, 2010, Pages 1284-1292

  Kettermann, Anna E ^a   Ferrucci, Luigi ^b   Trock, Bruce J ^a   Metter, E Jeffrey ^b   Loeb, Stacy ^a   Carter, H Ballentine ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

kinetics; prostate cancer; PSA; velocity

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; AGING; ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER SURVIVAL; DISEASE MARKER; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SURVIVAL TIME; CLINICAL PRACTICE; NOTE; PROGNOSIS; VELOCITY;

EID: 78349239709     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09363.x     Document Type: Article

References (29)

1. Carter HB, Pearson JD, Metter EJ, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992; 267: 2215-20
2. Carter HB, Ferrucci L, Kettermann A, et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 2006; 98: 1521-7
3. D'Amico AV, Chen MH, Roehl KA, et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004; 351: 125-35
4. D'Amico AV, Moul JW, Carroll PR, et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003; 95: 1376-83
5. Etzioni RD, Ankerst DP, Weiss NS, et al. Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence. J Natl Cancer Inst 2007; 99: 1510-5
6. Sengupta S, Myers RP, Slezak JM, et al. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol 2005; 174: 2191-6
7. Fall K, Garmo H, Andren O, et al. Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst 2007; 99: 526-32
8. Vickers AJ, Savage C, O'Brien MF, et al. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol 2009; 27: 398-403
9. Benecchi L, Pieri AM, Destro Pastizzaro C, et al. Optimal measure of PSA kinetics to identify prostate cancer. Urology 2008; 71: 390-4
10. Connolly D, Black A, Murray LJ, et al. Methods of calculating prostate-specific antigen velocity. Eur Urol 2007; 52: 1044-50
11. King CR, Freedland SJ, Terris MK, et al. Optimal timing, cutoff, and method of calculation of preoperative prostate-specific antigen velocity to predict relapse after prostatectomy: a report from SEARCH. Urology 2007; 69: 732-7
12. Riffenburgh RH, Amling CL,. Use of early PSA velocity to predict eventual abnormal PSA values in men at risk for prostate cancer. Prostate Cancer Prostatic Dis 2003; 6: 39-44
13. Yu X, Han M, Loeb S, et al. Comparison of methods for calculating prostate specific antigen velocity. J Urol 2006; 176: 2427-31
14. McGee D, Reed D, Yano K., The results of logistic analyses when the variables are highly correlated: an empirical example using diet and CHD incidence. J Chronic Dis 1984; 37: 713-9
15. Shock NW, Greulich RC, Andres R, et al. Normal Human Aging. The Baltimore Longitudinal Study of Aging. Washington, DC: US GPO (NIH publication no. 84-2450), 1984
16. SEER.; last accessed 23 February 2009
17. Schaeffer EM, Carter HB, Kettermann A, et al. Prostate specific antigen testing among the elderly-when to stop? J Urol 2009; 181: 1606-14
18. Schroder FH, Roobol MJ, Van Der Kwast TH, et al. Does PSA velocity predict prostate cancer in pre-screened populations? Eur Urol 2006; 49: 460-5
19. Glatting G, Kletting P, Reske SN, et al. Choosing the optimal fit function: comparison of the Akaike information criterion and the F-test. Med Phys 2007; 34: 4285-92
20. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157-72
21. Inoue LY, Etzioni R, Slate EH, et al. Combining longitudinal studies of PSA. Biostatistics 2004; 5: 483-500
22. Vickers AJ, Savage C, O'Brien MF, et al. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol 2009; 27: 398-403
23. Fall K, Garmo H, Andren O, et al. Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst 2007; 99: 526-32
24. O'Brien MF, Cronin AM, Fearn PA, et al. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. J Clin Oncol 2009; 27: 3591-7
25. Stephenson AJ, Kattan MW, Eastham JA, et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009; 27: 4300-5
26. Vickers AJ, Wolters T, Savage CJ, et al. Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort. Eur Urol 2009; August 7 (Epub ahead of print)
27. Eggener SE, Yossepowitch O, Roehl KA, Loeb S, Yu X, Catalona WJ,. Relationship of prostate-specific antigen velocity to histologic findings in a prostate cancer screening program. Urology 2008; 71: 1016-9
28. Ulmert D, Serio AM, O'Brien MF, et al. Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. J Clin Oncol 2008; 26: 835-41
29. Ross AE, Loeb S, Landis PK, et al. PSA kinetics alone are an unreliable trigger for intervention in a prostate cancer surveillance program. J Urol 2009; 181 (Suppl.): 178